David A. Siegel Lumos Pharma, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding LUMO
# of Institutions
42Shares Held
2.29MCall Options Held
0Put Options Held
0-
Wells Fargo & Company San Francisco, CA416KShares$914,2120.0% of portfolio
-
Goldman Sachs Group Inc New York, NY407KShares$894,5460.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$536,9800.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny218KShares$479,6300.0% of portfolio
-
Acuitas Investments, LLC141KShares$309,5150.21% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $18.5M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...